Strategic Intent: Rubedo’s Seno-Adaptive Bet On Longevity Medicine

In this episode of Strategic Intent, In Vivo senior reporter David Wild speaks with Frederick Beddingfield, CEO of Rubedo Life Sciences, about turning the biology of aging into real medicines. They discuss Rubedo’s lead topical GPX4 modulator RLS‑1496 in actinic keratosis, psoriasis, atopic dermatitis, and photo‑aged skin; a new push into androgenetic alopecia; and the company’s “seno-adaptive” approach to selectively clearing or rejuvenating aging cells. The conversation also explores Rubedo’s AI-enabled drug discovery platform, how dermatology can validate a broader longevity thesis, and what it will take for aging biology to become a credible, commercial drug category.